Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.77 |
| ▸ | GAK | O14976 | 1/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.63 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.63 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.63 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2354967 | 0.89 | MAPK14 (0.75) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL6158122 | 0.88 | MAPK14 (0.73) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL6162515 | 0.88 | MAPK14 (0.73) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL6159398 | 0.88 | MAPK14 (0.73) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL2358527 | 0.85 | MAPK14 (0.70) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL6159367 | 0.85 | MAPK14 (0.70) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL6159246 | 0.85 | MAPK14 (0.69) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL6160339 | 0.85 | MAPK14 (0.69) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL4731609 | 0.84 | MAPK14 (0.77) | MAPK14GAKLCKCYP3A4PDGFRB | |
| SCHEMBL6158206 | 0.84 | MAPK14 (0.71) | MAPK14GAKLCKCYP3A4PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4838121-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1641764-B1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| WO-2007096151-A2 | INHIBITORS OF P38-KINASE FOR TREATMENT OF PULMONARY HYPERTENSION | NOVARTIS AG (CH) | 2007-08-30 | — | — | WO | claimed |
| JP-2007521278-A | — | — | 2007-08-02 | — | — | JP | claimed |
| CN-1832928-A | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2006-09-13 | — | — | CN | claimed |
| EP-1641764-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | Novartis AG (CH) | 2006-04-05 | — | — | EP | claimed |
| EP-1075467-B1 | PYRAZOLE DERIVATIVES AS P-38 MAP KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | claimed |
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2005-03-03 | — | — | US | claimed |
| WO-2005009973-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-03 | — | — | WO | claimed |
| CN-1147476-C | Pyrazole derivatives as P-38 MAP kinase inhibitors | - | 2004-04-28 | — | — | CN | claimed |
| CN-1300282-A | Pyrazole derivatives as P-38 MAP kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2001-06-20 | — | — | CN | claimed |
| US-8580838-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20130172352-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8410160-B2 | 5-membered heterocycle-based P38 kinase inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120264801-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| EP-1218346-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-03 | — | — | EP | disclosed |
| US-6376527-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-6316466-B1 | Pyrazole derivatives P-38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| CN-1300282-A | Pyrazole derivatives as P-38 MAP kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2001-06-20 | — | — | CN | disclosed |
| WO-2001021591-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | MAPK14 33/4885GAK 62/4885LCK 131/4885 |
| US-20130172352-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | MAPK14 33/4885GAK 57/4885LCK 135/4885 |
| US-20120264801-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | MAPK14 33/4885GAK 57/4885LCK 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.